Elicio Therapeutics presents updated results from ELI-002 Phase 1 study

Elicio Therapeutics (ELTX) presented updated results from the Phase 1 AMPLIFY-201 clinical trial of ELI-002, an Amphiphile, AMP, cancer vaccine that targets KRAS-mutant tumors, at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland. ELI-002 was evaluated in individuals with mutant KRAS-driven colorectal or pancreatic cancer with residual circulating tumor DNA and/or serum tumor biomarkers, who remain at high risk of disease recurrence following standard locoregional treatment. Key observations include: A 16.3-month mRFS and 28.9-month mOS for the full study cohort; mRFS has not yet been reached in patients with above-median T cell responses; patients who achieved below-median T cell responses achieved a 4.0-month mRFS; Similar mRFS was observed between the PDAC subgroup, the CRC subgroup and the full study cohort; 28.9-month mOS was identical for the PDAC subgroup and the full study cohort, comparing favorably to a historical PDAC control group, mOS was not reached in the CRC subgroup; Ex vivo expansion of mKRAS-specific T cells with concomitant tumor biomarker reductions in most patients; ELI-002 2P was well-tolerated, with no Grade 3/4 treatment-emergent adverse events, dose-limiting toxicities or cases of cytokine release syndrome observed